![]() |
Technical Data |
|
T9160-03H |
Tumor Necrosis Factor alpha, Recombinant, Human (TNFa) |
100ug 500ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Tumor necrosis factor alpha (TNF-a), also called cachectin, consists of 158 amino acids. TNF-a is a 17.5kD factor produced by neutrophils, CD4+ T cells, macrophage, NK cells, LAK cells, astrocytes endothelial cells, and smooth muscle cells. TNF-a is cytolytic and plays an important role in immune regulation including hemorrhagic tumor necrosis/cytotoxicity and inflammation, and in regulation of antiviral and immune proliferative and activation responses. The active form of this protein is a trimer. Additional amino acid, methionine, was attached at N-terminus of the protein. Amino Acid Sequence: MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL Biological Activity: Measured in a cytotoxicity assay using L929 mouse fibrosarcoma cells in the presence of the metabolic inhibitor actinomycin D. The ED50 for this effect is <0.16ng/ml. Activity Assay: L929 cytotoxicity assay using actinomycin D Cell Number: 2 x 10,000 cells/well Incubation: 24hr after sample treatment Assay Media: 5% FBS media Cytokine Concentration: 12 pg/ml - 25 ng/ml Detection method: MTT assay Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing.. Store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: 17.5kD |
Source: Human, Recombinant, E. coli Purity: > 95% by SDS PAGE. Purified by using conventional chromatography techniques. Endotoxin: 1EU/ug protein (LAL method) Concentration: ~1mg/ml Form: Supplied as a liquid in PBS, pH 7.4 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Ruddle, N.H., et al., Curr. Opin. Immunol. 4: 327-332 (1992). 2. Chicoine, M.R., et al., J. Neurooncol. 35: 249-257 (1997). 3. Wingfield, P., et al., FEBS Lett. 211: 179-184 (1987). 4. Tikhonov, R.V., et al., Russ. J. Bioorg. Chem. 22: 141-144 (1996). 5. Barbara, J.A.J., et al., Proc. Natl. Acad. Sci. USA 83: 4533-4537 (1986).
|
||